Text on screen:
[UBRELVY logo]
UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Super:
PRESCRIBE UBRELVY TO TREAT MIGRAINE ATTACKS WHEN HEAD PAIN SPIKES OR BEFORE IT STRIKES¹

WHEN HEAD PAIN SPIKES
POWERFUL & RAPID

Text on screen:
Eliminates pain — 21% of patients experienced pain freedom at 2 hours (co-primary endpoint).* UBRELVY 100 mg (95/448) vs 12% placebo (54/456)^1,2
Relieves pain quickly — 61% of patients experienced pain relief at 2 hours (secondary endpoint).* UBRELVY 100 mg (275/448) vs 49% placebo (224/456)^1,3

Super:
BEFORE HEAD PAIN STRIKES
HEAD PAIN AVOIDANCE

Text on screen:
UBRELVY is the FIRST AND ONLY acute treatment for migraine with demonstrated prodrome data in a phase 3 clinical trial^4†
Data on patients who avoided moderate to severe headache pain when UBRELVY 100 mg was taken during prodrome⁴

*In pivotal clinical studies, patients took UBRELVY within 4 hours of migraine headache onset.^5
†The prodrome study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, crossover study in which the prodrome phase was defined as 1-6 hours prior to onset of headache.⁴

Laura and Traci are actual UBRELVY patients who were on prescribed therapy when they provided this testimonial. Changes in therapy status may have occurred since that time. Laura and Traci were compensated by AbbVie for sharing their stories.

Laura Real UBRELVY patient
Traci Real UBRELVY patient

Laura:
I always have UBRELVY with me.

Super:
UBRELVY CAN HELP WHEN HEAD PAIN SPIKES^1,2

Text on screen:
Laura Real UBRELVY patient

Laura:
It works.

Super:
POWERFUL & RAPID^1,2
21% OF PATIENTS EXPERIENCED PAIN FREEDOM AT 2 HOURS

Text on screen:
(co-primary endpoint)*
UBRELVY 100 mg (95/448) vs 12% placebo (54/456)^†
Stay tuned for study design and results for 50 mg at 2 hours.

*Pain freedom was defined as a reduction from moderate or severe headache pain to no pain.^1
†P<0.001.¹

Laura Real UBRELVY patient

Laura:
I know that I'll take it and within 2 hours...

Super:
POWERFUL & RAPID^1,3
61% OF PATIENTS EXPERIENCED PAIN RELIEF AT 2 HOURS

Text on screen:
(secondary endpoint)*
100 mg (275/448) vs 49% placebo (224/456)^†
Stay tuned for study design and results for 50 mg at 2 hours.

*In pivotal clinical studies, patients took UBRELVY within 4 hours of migraine headache onset.^5
†Pain relief was defined as a reduction in migraine pain from moderate or severe to mild or none postdose.¹

Laura:
...my migraine will start to go away.

Super:
TALK TO PATIENTS ABOUT THE EARLY SIGNS OF A MIGRAINE ATTACK BEFORE HEAD PAIN STRIKES

Text on screen:
In a separate phase 3 clinical trial, people studied were able to reliably predict a headache 1-6 hours before it started. Not everyone has pre-headache symptoms; some studied couldn't accurately predict their headaches.⁴
Educate your patients about early signs of a migraine attack.

Traci Real UBRELVY patient

Traci:
I can take my UBRELVY when I do have the early signs, like light sensitivity and pain in my neck.

Super:
HEAD PAIN AVOIDANCE⁴
UBRELVY® HAS DEMONSTRATED PRODROME DATA FOR TREATMENT EARLY IN THE MIGRAINE ATTACK FROM A PHASE 3 CLINICAL TRIAL.

Text on screen:
Data on patients who avoided moderate to severe headache pain when UBRELVY 100 mg was taken during prodrome.

Stay tuned for study design.

Traci Real UBRELVY patient

Traci:
I am so thankful that I found UBRELVY.

Text on screen:
Choose something different.
IT'S TIME TO START UBRELVY®.

Continue watching for details and for Important Safety Information.

Text on screen:
ACHIEVE PIVOTAL TRIALS DESIGN
Two randomized, double-blind, placebo-controlled, multicenter trials evaluated the efficacy and safety of UBRELVY in adults who had 2 to 8 migraine attacks of moderate to severe pain per month. Data were pooled for the 50 mg analysis. A co-primary endpoint at 2 hours for UBRELVY vs placebo was freedom from most bothersome symptom (photophobia, phonophobia, nausea): 50 mg: 39% (342/883) vs 28% (251/910) or 100 mg: 38% (169/448) vs 28% (126/454).^1,3,6

RESULTS AT 2 HOURS POSTDOSE WITH UBRELVY® 50 mg
Co-primary endpoint: Pain freedom at 2 hours with a single dose^7*
21% of patients (182/886) experienced pain freedom vs 13% placebo (119/912).^7†
Secondary endpoint: Pain relief at 2 hours with a single dose^7‡
62% of patients (547/886) experienced pain relief vs 49% placebo (444/912).^7†
*Pain freedom was defined as a reduction from moderate or severe headache pain to no pain.^1
†P<0.05.^1
‡Pain relief was defined as a reduction in migraine pain from moderate or severe to mild or none postdose.¹

PRODROME STUDY DESIGN
A phase 3, multicenter, randomized, double-blind, placebo-controlled, crossover study that evaluated the absence of headache pain of moderate to severe intensity within 24 hours postdose after taking a single dose of UBRELVY 100 mg during the prodrome phase. Of the 1087 patients who were screened for eligibility, 290 failed screening due to a qualifying event, including investigator judgment. See full study design on website for additional details.^4,8

LIMITATION: This study evaluated a subset of the migraine population who could reliably predict the onset of migraine headache pain (per clinician judgment) within a short time window. Patients should be carefully assessed on their ability to accurately predict the onset of a migraine attack and progression to the headache phase. The 50 mg dose was not assessed. Patients were not allowed to administer a second dose.

The most common TEAEs (≥2% in either group) were nausea (UBRELVY 5% vs placebo 3%), dizziness (2% vs 3%), fatigue (3% vs 2%), and somnolence (2% vs 1%).^4§

UBRELVY IS THE ONLY ACUTE TREATMENT FOR MIGRAINE THAT HAS DEMONSTRATED DATA IN THE PRODROME PHASE IN A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL⁴

TEAEs=treatment-emergent adverse events.
^§TEAEs reflected any adverse events reported within 48 hours after taking UBRELVY or placebo.⁴

ESTABLISHED SAFETY AND TOLERABILITY, WITH LONG-TERM SAFETY DATA

Graphic:
Table includes adverse reactions (ARs) from ACHIEVE I and II.¹ ARs occurring in at least 2% and at a frequency greater than placebo.⁴
No medication overuse headache has been shown with use⁹
The long-term safety of UBRELVY was further established in 813 patients in a 52-week, open-label trial with 31,968 doses given (UBRELVY 50 mg and 100 mg). In this study, discontinuation rates due to adverse reactions were <3%.¹⁰

Please see Important Safety Information at the end of this video or on the website below.

References: 1. UBRELVY [package insert]. North Chicago, IL: AbbVie Inc.; 2025. 2. Data on file. ACHIEVE I and ACHIEVE II Pain Freedom Timecourse Tables. AbbVie Inc. 3. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230-2241. 4. Dodick DW, Goadsby PJ, Schwedt TJ, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023;402(10419):2307-2316. 5. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II. Headache. 2020;60(4):686-700. 6. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887-1898. 7. Hutchinson S, Dodick DW, Treppendahl C, et al. Ubrogepant for the acute treatment of migraine: pooled efficacy, safety, and tolerability from the ACHIEVE I and ACHIEVE II phase 3 randomized trials. Neurol Ther. 2021;10(1):235-249. 8. Data on file. AbbVie Inc. 9. Ailani J, Burch RC, Robbins MS. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039. 10. Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141-152.